Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
about
Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsyTreatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairmentRational Polytherapy with Antiepileptic Drugs.Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective.Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.The role of levetiracetam in treatment of seizures in brain tumor patients.Levetiracetam: a comprehensive review.Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.Seizures in low- and high-grade gliomas: current management and future outlook.Brivaracetam for the treatment of epilepsy.Spotlight on levetiracetam in epilepsy.Methodologies used to identify and characterize interactions among antiepileptic drugs.Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays.Seizures in oligodendroglial tumors.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Computational approaches for innovative antiepileptic drug discovery.Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapyUtilization patterns of antiepileptic drugs among adult epileptic patients at a tertiary hospital in Oman.Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
P2860
Q26859135-07BB7461-B72D-43EE-B210-50B8DDA90E2CQ33645744-F2C42602-F1EE-4E81-9225-A4984D2529E2Q33664046-C953FAE4-19E7-41A8-AD65-FB61E33630CEQ36097620-66BDBC8C-365E-4C63-840C-ED8D7E14A7F0Q36943913-361DC9F4-AA04-49C5-9526-957A8358A4DBQ37217443-AF2A2AE1-5685-4392-8382-C7066E60098EQ37688063-A3D0BF81-293C-4A50-B975-1056C634E4F8Q37722610-DF428F71-E676-4085-94A4-E8F7F9986E9EQ37752365-863C0C58-EDA5-431C-B63B-8D7FFFF68E68Q37891095-F8B32311-F4A9-4705-B5FE-337327C10FF7Q37936429-691D0164-231A-4FCF-AA99-56CB45B5A199Q38018676-A56F03C9-6648-4688-8519-881F91E9FC76Q38344749-6D70A89A-DCB7-4BA5-953D-CD3F2D5D7A55Q38610571-69A995AD-24F1-46CA-B301-720DBC5DBD2BQ38614499-7AB0B0B0-9670-4D8B-B11D-05516360DBDAQ38907478-E578F9E6-4EAD-4381-82EF-CD02789C218EQ41376779-40D9AAA0-55AC-4A58-8FB8-E8EEC99D1DCCQ46489939-C70FC895-9350-48FA-8A16-61B2558E6F21Q48114674-8D2D8327-3942-41F2-ABBF-C79A064B1036Q48886998-861299BF-BBC1-49E5-9697-7E06DD981A11
P2860
Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefit of combination therapy ...... l evidence with levetiracetam.
@en
Benefit of combination therapy ...... l evidence with levetiracetam.
@nl
type
label
Benefit of combination therapy ...... l evidence with levetiracetam.
@en
Benefit of combination therapy ...... l evidence with levetiracetam.
@nl
prefLabel
Benefit of combination therapy ...... l evidence with levetiracetam.
@en
Benefit of combination therapy ...... l evidence with levetiracetam.
@nl
P2093
P1433
P1476
Benefit of combination therapy ...... l evidence with levetiracetam.
@en
P2093
Alain Matagne
Henrik Klitgaard
Philip N Patsalos
Rafal M Kaminski
P304
P356
10.1111/J.1528-1167.2008.01713.X
P577
2008-07-08T00:00:00Z